VP-102
Jan 21, 2020
Imfinzi combo gets ODD; Mayzent gets EU nod; Positive results of VP-102
The US FDA has recently granted Orphan Drug Designation to AstraZeneca’s Imfinzi (durvalumab) and tremelimumab, combination therapy for HCC. Imfinzi, a monoclonal antibody, binds and inhibits the interaction of PD-L1 with PD-1 and CD80. The drug blocks tumour’s immune-evading mechanism and releases the inhibiti...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
